Interactions between Verapamil and Digoxin in Langendorff‐Perfused Rat Hearts: The Role of Inhibition of P‐glycoprotein in the Heart

:  P‐glycoprotein (P‐gp) is expressed in tumour cells as well as normal tissues including heart. Modulation of P‐gp transport in vivo may lead to increased drug penetrance to tissues with resulting increases in toxicity. We aimed to investigate the effects of P‐gp on the isolated heart by digoxin in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Basic & clinical pharmacology & toxicology 2010-11, Vol.107 (5), p.847-852
Hauptverfasser: Aylin Arici, Mualla, Kilinc, Emrah, Demir, Omer, Ates, Mehmet, Yesilyurt, Alaattin, Gelal, Ayse
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 852
container_issue 5
container_start_page 847
container_title Basic & clinical pharmacology & toxicology
container_volume 107
creator Aylin Arici, Mualla
Kilinc, Emrah
Demir, Omer
Ates, Mehmet
Yesilyurt, Alaattin
Gelal, Ayse
description :  P‐glycoprotein (P‐gp) is expressed in tumour cells as well as normal tissues including heart. Modulation of P‐gp transport in vivo may lead to increased drug penetrance to tissues with resulting increases in toxicity. We aimed to investigate the effects of P‐gp on the isolated heart by digoxin infusion in the absence and presence of verapamil. The study was performed in Langendorff isolated perfused rat hearts. After a 20 min. stabilisation period with Tyrode Buffer, digoxin (125 μg/5 mL) was infused for 10 min. in the control group (n = 7). The same dose of digoxin was infused during perfusion with verapamil (1 nm) containing Tyrode Buffer (n = 8) in the study group. Outflow concentration and cardiac parameters of digoxin were measured at frequent intervals for 40 min. AUEC(0–40 min) for left ventricular developed pressure was significantly increased in the presence of verapamil (4260 ± 39.37 mmHg min versus 4607 ± 98.09 mmHg min; 95% CI ‐587.7 to −105.8; p = 0.0083). The significant increases in left ventricular developed pressure were at 20, 25, 30, 35 and 40 min. AUC(0–40 min) value for outflow digoxin concentration‐time curve was significantly lower in the presence of verapamil. Verapamil increased the positive inotropic effect of digoxin, probably through the inhibition of P‐gp, which effluxes digoxin out of cardiac cells.
doi_str_mv 10.1111/j.1742-7843.2010.00574.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_954593308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1010636809</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5474-720a450fd2b4caa78477f7c45a5dc5bfe0a15b88f741330611eb615f316e83cd3</originalsourceid><addsrcrecordid>eNqNkU1vGyEQhldVo-aj_QsVl6q92IUFlnWlHlr3I5Ys1YrcXhHLDg7WmnVgrdi3HHvMb8wv6WzsuLeqCAkYnncY5s0ywuiQ4Xi_HDIl8oEqBR_mFKOUSiWG22fZ2fHi-XHP5Wl2ntKS0lwJRl9kp3kuhRwV6iz7PQkdRGM734ZEKuhuAQL5haG1WfmGmFCTL37Rbn0gOKcmLCDUbXTu4e5-BtFtEtTkynTkEkzs0gcyvwZy1TZAWkcm4dpXvs_dn2YoWTQ7265j28E-YYf0o_JlduJMk-DVYb3Ifn77Oh9fDqY_vk_Gn6YDK4USA5VTIyR1dV4Jawx-VCmnrJBG1lZWDqhhsipLhz_lnBaMQVUw6TgroOS25hfZ231eLOJmA6nTK58sNI0J0G6SHvWdQWWJ5Lt_kgwbX_CipCNEyz1qY5tSBKfX0a9M3CGke8f0Uvdm6N4Y3TumHx3TW5S-PryyqVZQH4VPFiHw5gCYZE3jognWp78c1ppzSZH7uOdufQO7_y5Afx7P5rjjfwCSUrPX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1010636809</pqid></control><display><type>article</type><title>Interactions between Verapamil and Digoxin in Langendorff‐Perfused Rat Hearts: The Role of Inhibition of P‐glycoprotein in the Heart</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Aylin Arici, Mualla ; Kilinc, Emrah ; Demir, Omer ; Ates, Mehmet ; Yesilyurt, Alaattin ; Gelal, Ayse</creator><creatorcontrib>Aylin Arici, Mualla ; Kilinc, Emrah ; Demir, Omer ; Ates, Mehmet ; Yesilyurt, Alaattin ; Gelal, Ayse</creatorcontrib><description>:  P‐glycoprotein (P‐gp) is expressed in tumour cells as well as normal tissues including heart. Modulation of P‐gp transport in vivo may lead to increased drug penetrance to tissues with resulting increases in toxicity. We aimed to investigate the effects of P‐gp on the isolated heart by digoxin infusion in the absence and presence of verapamil. The study was performed in Langendorff isolated perfused rat hearts. After a 20 min. stabilisation period with Tyrode Buffer, digoxin (125 μg/5 mL) was infused for 10 min. in the control group (n = 7). The same dose of digoxin was infused during perfusion with verapamil (1 nm) containing Tyrode Buffer (n = 8) in the study group. Outflow concentration and cardiac parameters of digoxin were measured at frequent intervals for 40 min. AUEC(0–40 min) for left ventricular developed pressure was significantly increased in the presence of verapamil (4260 ± 39.37 mmHg min versus 4607 ± 98.09 mmHg min; 95% CI ‐587.7 to −105.8; p = 0.0083). The significant increases in left ventricular developed pressure were at 20, 25, 30, 35 and 40 min. AUC(0–40 min) value for outflow digoxin concentration‐time curve was significantly lower in the presence of verapamil. Verapamil increased the positive inotropic effect of digoxin, probably through the inhibition of P‐gp, which effluxes digoxin out of cardiac cells.</description><identifier>ISSN: 1742-7835</identifier><identifier>EISSN: 1742-7843</identifier><identifier>DOI: 10.1111/j.1742-7843.2010.00574.x</identifier><identifier>PMID: 22545967</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists &amp; inhibitors ; Biological and medical sciences ; Chromatography, High Pressure Liquid ; digoxin ; Digoxin - pharmacokinetics ; Digoxin - pharmacology ; Drug Interactions ; Drugs ; Female ; Heart ; Heart Rate - drug effects ; Heart Ventricles - drug effects ; Heart Ventricles - metabolism ; In Vitro Techniques ; Medical sciences ; P-Glycoprotein ; Perfusion ; Pharmacology. Drug treatments ; Pressure ; Rats ; Rats, Wistar ; Toxicity ; Ventricle ; Ventricular Function, Left - drug effects ; Verapamil ; Verapamil - pharmacokinetics ; Verapamil - pharmacology</subject><ispartof>Basic &amp; clinical pharmacology &amp; toxicology, 2010-11, Vol.107 (5), p.847-852</ispartof><rights>2010 The Authors. Basic &amp; Clinical Pharmacology &amp; Toxicology © 2010 Nordic Pharmacological Society</rights><rights>2015 INIST-CNRS</rights><rights>2010 The Authors. Basic &amp; Clinical Pharmacology &amp; Toxicology © 2010 Nordic Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5474-720a450fd2b4caa78477f7c45a5dc5bfe0a15b88f741330611eb615f316e83cd3</citedby><cites>FETCH-LOGICAL-c5474-720a450fd2b4caa78477f7c45a5dc5bfe0a15b88f741330611eb615f316e83cd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1742-7843.2010.00574.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1742-7843.2010.00574.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23302350$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22545967$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aylin Arici, Mualla</creatorcontrib><creatorcontrib>Kilinc, Emrah</creatorcontrib><creatorcontrib>Demir, Omer</creatorcontrib><creatorcontrib>Ates, Mehmet</creatorcontrib><creatorcontrib>Yesilyurt, Alaattin</creatorcontrib><creatorcontrib>Gelal, Ayse</creatorcontrib><title>Interactions between Verapamil and Digoxin in Langendorff‐Perfused Rat Hearts: The Role of Inhibition of P‐glycoprotein in the Heart</title><title>Basic &amp; clinical pharmacology &amp; toxicology</title><addtitle>Basic Clin Pharmacol Toxicol</addtitle><description>:  P‐glycoprotein (P‐gp) is expressed in tumour cells as well as normal tissues including heart. Modulation of P‐gp transport in vivo may lead to increased drug penetrance to tissues with resulting increases in toxicity. We aimed to investigate the effects of P‐gp on the isolated heart by digoxin infusion in the absence and presence of verapamil. The study was performed in Langendorff isolated perfused rat hearts. After a 20 min. stabilisation period with Tyrode Buffer, digoxin (125 μg/5 mL) was infused for 10 min. in the control group (n = 7). The same dose of digoxin was infused during perfusion with verapamil (1 nm) containing Tyrode Buffer (n = 8) in the study group. Outflow concentration and cardiac parameters of digoxin were measured at frequent intervals for 40 min. AUEC(0–40 min) for left ventricular developed pressure was significantly increased in the presence of verapamil (4260 ± 39.37 mmHg min versus 4607 ± 98.09 mmHg min; 95% CI ‐587.7 to −105.8; p = 0.0083). The significant increases in left ventricular developed pressure were at 20, 25, 30, 35 and 40 min. AUC(0–40 min) value for outflow digoxin concentration‐time curve was significantly lower in the presence of verapamil. Verapamil increased the positive inotropic effect of digoxin, probably through the inhibition of P‐gp, which effluxes digoxin out of cardiac cells.</description><subject>Animals</subject><subject>ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists &amp; inhibitors</subject><subject>Biological and medical sciences</subject><subject>Chromatography, High Pressure Liquid</subject><subject>digoxin</subject><subject>Digoxin - pharmacokinetics</subject><subject>Digoxin - pharmacology</subject><subject>Drug Interactions</subject><subject>Drugs</subject><subject>Female</subject><subject>Heart</subject><subject>Heart Rate - drug effects</subject><subject>Heart Ventricles - drug effects</subject><subject>Heart Ventricles - metabolism</subject><subject>In Vitro Techniques</subject><subject>Medical sciences</subject><subject>P-Glycoprotein</subject><subject>Perfusion</subject><subject>Pharmacology. Drug treatments</subject><subject>Pressure</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Toxicity</subject><subject>Ventricle</subject><subject>Ventricular Function, Left - drug effects</subject><subject>Verapamil</subject><subject>Verapamil - pharmacokinetics</subject><subject>Verapamil - pharmacology</subject><issn>1742-7835</issn><issn>1742-7843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1vGyEQhldVo-aj_QsVl6q92IUFlnWlHlr3I5Ys1YrcXhHLDg7WmnVgrdi3HHvMb8wv6WzsuLeqCAkYnncY5s0ywuiQ4Xi_HDIl8oEqBR_mFKOUSiWG22fZ2fHi-XHP5Wl2ntKS0lwJRl9kp3kuhRwV6iz7PQkdRGM734ZEKuhuAQL5haG1WfmGmFCTL37Rbn0gOKcmLCDUbXTu4e5-BtFtEtTkynTkEkzs0gcyvwZy1TZAWkcm4dpXvs_dn2YoWTQ7265j28E-YYf0o_JlduJMk-DVYb3Ifn77Oh9fDqY_vk_Gn6YDK4USA5VTIyR1dV4Jawx-VCmnrJBG1lZWDqhhsipLhz_lnBaMQVUw6TgroOS25hfZ231eLOJmA6nTK58sNI0J0G6SHvWdQWWJ5Lt_kgwbX_CipCNEyz1qY5tSBKfX0a9M3CGke8f0Uvdm6N4Y3TumHx3TW5S-PryyqVZQH4VPFiHw5gCYZE3jognWp78c1ppzSZH7uOdufQO7_y5Afx7P5rjjfwCSUrPX</recordid><startdate>201011</startdate><enddate>201011</enddate><creator>Aylin Arici, Mualla</creator><creator>Kilinc, Emrah</creator><creator>Demir, Omer</creator><creator>Ates, Mehmet</creator><creator>Yesilyurt, Alaattin</creator><creator>Gelal, Ayse</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201011</creationdate><title>Interactions between Verapamil and Digoxin in Langendorff‐Perfused Rat Hearts: The Role of Inhibition of P‐glycoprotein in the Heart</title><author>Aylin Arici, Mualla ; Kilinc, Emrah ; Demir, Omer ; Ates, Mehmet ; Yesilyurt, Alaattin ; Gelal, Ayse</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5474-720a450fd2b4caa78477f7c45a5dc5bfe0a15b88f741330611eb615f316e83cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists &amp; inhibitors</topic><topic>Biological and medical sciences</topic><topic>Chromatography, High Pressure Liquid</topic><topic>digoxin</topic><topic>Digoxin - pharmacokinetics</topic><topic>Digoxin - pharmacology</topic><topic>Drug Interactions</topic><topic>Drugs</topic><topic>Female</topic><topic>Heart</topic><topic>Heart Rate - drug effects</topic><topic>Heart Ventricles - drug effects</topic><topic>Heart Ventricles - metabolism</topic><topic>In Vitro Techniques</topic><topic>Medical sciences</topic><topic>P-Glycoprotein</topic><topic>Perfusion</topic><topic>Pharmacology. Drug treatments</topic><topic>Pressure</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Toxicity</topic><topic>Ventricle</topic><topic>Ventricular Function, Left - drug effects</topic><topic>Verapamil</topic><topic>Verapamil - pharmacokinetics</topic><topic>Verapamil - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aylin Arici, Mualla</creatorcontrib><creatorcontrib>Kilinc, Emrah</creatorcontrib><creatorcontrib>Demir, Omer</creatorcontrib><creatorcontrib>Ates, Mehmet</creatorcontrib><creatorcontrib>Yesilyurt, Alaattin</creatorcontrib><creatorcontrib>Gelal, Ayse</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Basic &amp; clinical pharmacology &amp; toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aylin Arici, Mualla</au><au>Kilinc, Emrah</au><au>Demir, Omer</au><au>Ates, Mehmet</au><au>Yesilyurt, Alaattin</au><au>Gelal, Ayse</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interactions between Verapamil and Digoxin in Langendorff‐Perfused Rat Hearts: The Role of Inhibition of P‐glycoprotein in the Heart</atitle><jtitle>Basic &amp; clinical pharmacology &amp; toxicology</jtitle><addtitle>Basic Clin Pharmacol Toxicol</addtitle><date>2010-11</date><risdate>2010</risdate><volume>107</volume><issue>5</issue><spage>847</spage><epage>852</epage><pages>847-852</pages><issn>1742-7835</issn><eissn>1742-7843</eissn><abstract>:  P‐glycoprotein (P‐gp) is expressed in tumour cells as well as normal tissues including heart. Modulation of P‐gp transport in vivo may lead to increased drug penetrance to tissues with resulting increases in toxicity. We aimed to investigate the effects of P‐gp on the isolated heart by digoxin infusion in the absence and presence of verapamil. The study was performed in Langendorff isolated perfused rat hearts. After a 20 min. stabilisation period with Tyrode Buffer, digoxin (125 μg/5 mL) was infused for 10 min. in the control group (n = 7). The same dose of digoxin was infused during perfusion with verapamil (1 nm) containing Tyrode Buffer (n = 8) in the study group. Outflow concentration and cardiac parameters of digoxin were measured at frequent intervals for 40 min. AUEC(0–40 min) for left ventricular developed pressure was significantly increased in the presence of verapamil (4260 ± 39.37 mmHg min versus 4607 ± 98.09 mmHg min; 95% CI ‐587.7 to −105.8; p = 0.0083). The significant increases in left ventricular developed pressure were at 20, 25, 30, 35 and 40 min. AUC(0–40 min) value for outflow digoxin concentration‐time curve was significantly lower in the presence of verapamil. Verapamil increased the positive inotropic effect of digoxin, probably through the inhibition of P‐gp, which effluxes digoxin out of cardiac cells.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22545967</pmid><doi>10.1111/j.1742-7843.2010.00574.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1742-7835
ispartof Basic & clinical pharmacology & toxicology, 2010-11, Vol.107 (5), p.847-852
issn 1742-7835
1742-7843
language eng
recordid cdi_proquest_miscellaneous_954593308
source MEDLINE; Access via Wiley Online Library; Alma/SFX Local Collection
subjects Animals
ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors
Biological and medical sciences
Chromatography, High Pressure Liquid
digoxin
Digoxin - pharmacokinetics
Digoxin - pharmacology
Drug Interactions
Drugs
Female
Heart
Heart Rate - drug effects
Heart Ventricles - drug effects
Heart Ventricles - metabolism
In Vitro Techniques
Medical sciences
P-Glycoprotein
Perfusion
Pharmacology. Drug treatments
Pressure
Rats
Rats, Wistar
Toxicity
Ventricle
Ventricular Function, Left - drug effects
Verapamil
Verapamil - pharmacokinetics
Verapamil - pharmacology
title Interactions between Verapamil and Digoxin in Langendorff‐Perfused Rat Hearts: The Role of Inhibition of P‐glycoprotein in the Heart
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-31T00%3A03%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interactions%20between%20Verapamil%20and%20Digoxin%20in%20Langendorff%E2%80%90Perfused%20Rat%20Hearts:%20The%20Role%20of%20Inhibition%20of%20P%E2%80%90glycoprotein%20in%20the%20Heart&rft.jtitle=Basic%20&%20clinical%20pharmacology%20&%20toxicology&rft.au=Aylin%20Arici,%20Mualla&rft.date=2010-11&rft.volume=107&rft.issue=5&rft.spage=847&rft.epage=852&rft.pages=847-852&rft.issn=1742-7835&rft.eissn=1742-7843&rft_id=info:doi/10.1111/j.1742-7843.2010.00574.x&rft_dat=%3Cproquest_cross%3E1010636809%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1010636809&rft_id=info:pmid/22545967&rfr_iscdi=true